Can you take Kerendia (finerenone) and Jardiance (empagliflozin) together?
Yes. Kerendia (finerenone) and Jardiance (empagliflozin) are commonly used together in people who have chronic kidney disease (CKD) with type 2 diabetes, because they target different pathways that both help slow disease progression and reduce cardiovascular risk.
What does the combination do for kidney and heart outcomes?
Using an SGLT2 inhibitor (Jardiance) alongside a nonsteroidal mineralocorticoid receptor antagonist (Kerendia) is intended to combine benefits:
- Jardiance helps the kidneys by increasing glucose and sodium excretion and lowering intraglomerular pressure, which can slow CKD progression.
- Kerendia helps by blocking mineralocorticoid receptor signaling, which can reduce inflammation and fibrosis linked to CKD and heart disease.
What are the main safety issues when both are used?
The key practical safety concern with the Kerendia + Jardiance combination is electrolyte and kidney function monitoring.
People using both typically need clinician follow-up for:
- Potassium (Kerendia can raise potassium; Jardiance usually lowers the risk of high potassium, but monitoring still matters)
- Kidney function (creatinine/eGFR changes can occur after starting or adjusting therapy)
- Volume status and blood pressure (Jardiance can cause more urination and can contribute to low blood pressure or dehydration in susceptible patients)
What side effects are patients most likely to notice?
With Jardiance and Kerendia together, patients often ask about:
- More urination, thirst, or dizziness (more typical with Jardiance)
- Possible genital yeast infections or urinary symptoms (more typical with SGLT2 inhibitors like Jardiance)
- Hyperkalemia symptoms are not always noticeable, which is why blood tests are important for Kerendia users
Do they interact directly?
There is no common “direct drug-drug interaction” that makes the combination automatically unsafe, but each drug affects kidney-related physiology and electrolytes. That’s why clinicians typically check labs after initiation and after dose changes, especially potassium and kidney function.
Is this combination recommended for everyone with diabetes and CKD?
Usually, the combination is considered when someone has type 2 diabetes plus CKD and is at risk for kidney and cardiovascular events. Whether it’s the right choice depends on:
- Current eGFR (kidney function)
- Baseline potassium
- Blood pressure and diuretic use
- Prior intolerance (for example, recurrent genital infections on an SGLT2 inhibitor)
What if potassium is high on Kerendia?
If potassium rises:
- Clinicians may adjust the Kerendia dose, stop it, or address contributing factors (dietary potassium, other medications that raise potassium).
- Patients are often counseled not to start potassium supplements or salt substitutes containing potassium without medical advice.
Which one comes first?
In practice, many clinicians start with an SGLT2 inhibitor (Jardiance) in appropriate patients, then add Kerendia when additional kidney/cardiovascular risk reduction is needed and lab values (especially potassium) are safe for finerenone. The exact sequence depends on kidney function, potassium, and tolerance.
If you share the patient’s eGFR and potassium (and current doses), I can help interpret what clinicians usually look for when deciding whether to combine Kerendia and Jardiance.